Clinical Trial: LEV102 Topical Gel in Acquired Blepharoptosis

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL

Official Title: A Phase 1/2a Study of LEV102 Topical Gel in Subjects With Acquired Blepharoptosis

Brief Summary: Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, multiple-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.

Detailed Summary: This is a Phase 1/2a, multicenter, randomized, vehicle-controlled, double-masked, single-dose, parallel-group study conducted in adult subjects with acquired blepharoptosis.
Subjects will receive a one-time application of randomized, double-masked IP.
Approximately 30 subjects will be enrolled in this study.
Eligible subjects will be randomized to 1 of the following 3 treatment groups in a 1:1:1 ratio and will receive a single dose of double-masked IP externally on the upper eyelid of both eyes (OU):
Sponsor: Levation Pharma, Ltd.

Current Primary Outcome: Adverse events

Original Primary Outcome: Adverse events

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Levation Pharma, Ltd.

Dates:
Date Received: January 27, 2023
Date Started: February 28, 2023
Date Completion: February 28, 2023
Last Updated: March 05, 2023
Last Verified: March 01, 2023